Does the media favor CRL or TECH?

In the previous week, Bio-Techne had 5 more articles in the media than Charles River Laboratories International. MarketBeat recorded 10 mentions for Bio-Techne and 5 mentions for Charles River Laboratories International. Bio-Techne's average media sentiment score of 1.19 beat Charles River Laboratories International's score of 0.57 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRL or IQV?

In the previous week, IQVIA had 3 more articles in the media than Charles River Laboratories International. MarketBeat recorded 8 mentions for IQVIA and 5 mentions for Charles River Laboratories International. IQVIA's average media sentiment score of 0.75 beat Charles River Laboratories International's score of 0.57 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Charles River Laboratories International (CRL) Competitors

$277.71 -3.96 (-1.41%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$277.84 +0.13 (+0.05%)

As of 09/18/2026 07:30 PM Eastern

Compare

CRL vs. ICLR, TECH, A, IQV, and RVTY

Should you buy Charles River Laboratories International stock or one of its competitors? Charles River Laboratories International's main competitors and comparable companies include Icon (ICLR), Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), and Revvity (RVTY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Charles River Laboratories International compare to Icon?

Icon (NASDAQ:ICLR) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Icon presently has a consensus price target of $170.07, indicating a potential upside of 3.63%. Charles River Laboratories International has a consensus price target of $273.81, indicating a potential downside of 1.40%. Given Icon's higher probable upside, research analysts clearly believe Icon is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Icon has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Icon has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25B	1.52	$229.34M	$4.26	38.52
Charles River Laboratories International	$4.02B	3.30	-$144.34M	-$4.85	N/A

In the previous week, Icon had 6 more articles in the media than Charles River Laboratories International. MarketBeat recorded 11 mentions for Icon and 5 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.57 beat Icon's score of 0.21 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Charles River Laboratories International	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Icon has a net margin of 3.99% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Charles River Laboratories International	-5.96%	15.75%	6.51%

95.6% of Icon shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 44.0% of Icon shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Icon beats Charles River Laboratories International on 9 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to Bio-Techne?

Charles River Laboratories International (NYSE:CRL) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Charles River Laboratories International currently has a consensus price target of $273.81, suggesting a potential downside of 1.40%. Bio-Techne has a consensus price target of $68.92, suggesting a potential downside of 4.76%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, equities analysts clearly believe Charles River Laboratories International is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Bio-Techne had 5 more articles in the media than Charles River Laboratories International. MarketBeat recorded 10 mentions for Bio-Techne and 5 mentions for Charles River Laboratories International. Bio-Techne's average media sentiment score of 1.19 beat Charles River Laboratories International's score of 0.57 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.30	-$144.34M	-$4.85	N/A
Bio-Techne	$1.22B	9.34	$181.86M	$1.15	62.93

Bio-Techne has a net margin of 14.97% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Bio-Techne	14.97%	13.23%	10.61%

Summary

Bio-Techne beats Charles River Laboratories International on 9 of the 15 factors compared between the two stocks.

How does Charles River Laboratories International compare to Agilent Technologies?

Charles River Laboratories International (NYSE:CRL) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Charles River Laboratories International currently has a consensus target price of $273.81, indicating a potential downside of 1.40%. Agilent Technologies has a consensus target price of $170.33, indicating a potential upside of 9.02%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.80

Charles River Laboratories International has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Agilent Technologies has a net margin of 19.53% compared to Charles River Laboratories International's net margin of -5.96%. Agilent Technologies' return on equity of 24.45% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Agilent Technologies	19.53%	24.45%	13.09%

98.9% of Charles River Laboratories International shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.30	-$144.34M	-$4.85	N/A
Agilent Technologies	$6.95B	6.34	$1.30B	$5.08	30.76

In the previous week, Agilent Technologies had 4 more articles in the media than Charles River Laboratories International. MarketBeat recorded 9 mentions for Agilent Technologies and 5 mentions for Charles River Laboratories International. Agilent Technologies' average media sentiment score of 1.11 beat Charles River Laboratories International's score of 0.57 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Agilent Technologies beats Charles River Laboratories International on 14 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to IQVIA?

Charles River Laboratories International (NYSE:CRL) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.30	-$144.34M	-$4.85	N/A
IQVIA	$16.31B	2.69	$1.36B	$8.06	33.09

Charles River Laboratories International has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, IQVIA had 3 more articles in the media than Charles River Laboratories International. MarketBeat recorded 8 mentions for IQVIA and 5 mentions for Charles River Laboratories International. IQVIA's average media sentiment score of 0.75 beat Charles River Laboratories International's score of 0.57 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA has a net margin of 8.10% compared to Charles River Laboratories International's net margin of -5.96%. IQVIA's return on equity of 30.25% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
IQVIA	8.10%	30.25%	6.54%

Charles River Laboratories International currently has a consensus price target of $273.81, suggesting a potential downside of 1.40%. IQVIA has a consensus price target of $248.00, suggesting a potential downside of 7.01%. Given Charles River Laboratories International's higher possible upside, research analysts clearly believe Charles River Laboratories International is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

IQVIA beats Charles River Laboratories International on 13 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to Revvity?

Charles River Laboratories International (NYSE:CRL) and Revvity (NYSE:RVTY) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, Revvity had 6 more articles in the media than Charles River Laboratories International. MarketBeat recorded 11 mentions for Revvity and 5 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.57 beat Revvity's score of 0.55 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Charles River Laboratories International currently has a consensus target price of $273.81, indicating a potential downside of 1.40%. Revvity has a consensus target price of $116.57, indicating a potential downside of 18.82%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, analysts plainly believe Charles River Laboratories International is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Revvity	0 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Revvity has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.30	-$144.34M	-$4.85	N/A
Revvity	$2.86B	5.61	$241.20M	$2.10	68.38

Revvity has a net margin of 8.16% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Revvity	8.16%	8.34%	5.01%

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Comparatively, 0.9% of Revvity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Charles River Laboratories International has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Revvity has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Summary

Charles River Laboratories International beats Revvity on 10 of the 16 factors compared between the two stocks.

Get Charles River Laboratories International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRL vs. The Competition

Export

Metric	Charles River Laboratories International	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$13.45B	$10.48B	$7.26B	$23.16B
Dividend Yield	N/A	1.46%	2.57%	3.59%
P/E Ratio	-57.26	70.70	275.79	28.21
Price / Sales	3.30	108.70	695.58	19.15
Price / Cash	12.83	27.34	77.42	34.53
Price / Book	4.31	5.70	10.46	4.67
Net Income	-$144.34M	$56.67B	$3.49B	$1.07B
7 Day Performance	-0.11%	4.59%	0.59%	-1.64%
1 Month Performance	-4.29%	1.52%	-2.01%	-4.25%
1 Year Performance	78.80%	28.13%	18.09%	8.32%

Charles River Laboratories International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRL Charles River Laboratories International	1.9611 of 5 stars	$277.71 -1.4%	$273.81 -1.4%	+76.8%	$13.45B	$4.02B	N/A	19,700	Analyst Forecast
ICLR Icon	2.657 of 5 stars	$173.94 +0.9%	$170.40 -2.0%	-8.5%	$13.20B	$8.25B	40.83	40,100	News Coverage Analyst Forecast Insider Trade
TECH Bio-Techne	3.3331 of 5 stars	$72.33 0.0%	$68.92 -4.7%	+36.6%	$11.34B	$1.22B	62.90	3,000	Positive News
A Agilent Technologies	4.296 of 5 stars	$153.46 +2.1%	$170.33 +11.0%	+22.4%	$42.37B	$6.95B	30.21	18,100	Positive News Dividend Announcement
IQV IQVIA	3.4921 of 5 stars	$269.54 0.0%	$243.63 -9.6%	+40.2%	$44.39B	$16.31B	33.44	93,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CRL) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Summary

How does Charles River Laboratories International compare to IQVIA?

Summary

How does Charles River Laboratories International compare to Revvity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Do analysts prefer ICLR or CRL?

Which has more volatility and risk, ICLR or CRL?

Which has higher earnings and valuation, ICLR or CRL?

Does the media refer more to ICLR or CRL?

Is ICLR or CRL more profitable?

Do institutionals and insiders believe in ICLR or CRL?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Which has more risk & volatility, CRL or TECH?

Do analysts recommend CRL or TECH?

Do insiders & institutionals have more ownership in CRL or TECH?

Does the media favor CRL or TECH?

Which has better valuation and earnings, CRL or TECH?

Is CRL or TECH more profitable?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Do analysts recommend CRL or A?

Which has more risk & volatility, CRL or A?

Is CRL or A more profitable?

Do institutionals and insiders believe in CRL or A?

Which has preferable valuation & earnings, CRL or A?

Does the media prefer CRL or A?

Summary

How does Charles River Laboratories International compare to IQVIA?

Which has better earnings and valuation, CRL or IQV?

Which has more volatility and risk, CRL or IQV?

Do institutionals and insiders hold more shares of CRL or IQV?

Does the media prefer CRL or IQV?

Is CRL or IQV more profitable?

Do analysts prefer CRL or IQV?

Summary

How does Charles River Laboratories International compare to Revvity?

Does the media prefer CRL or RVTY?

Do analysts rate CRL or RVTY?

Which has higher earnings & valuation, CRL or RVTY?

Is CRL or RVTY more profitable?

Do insiders & institutionals believe in CRL or RVTY?

Which has more risk & volatility, CRL or RVTY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools